Share on LinkedInShare on LinkedIn

ARTICLE · 06 NOVEMBER 2015

Patentability Of Genetic Material

The patentability of genetic material has again come into the spotlight with the recent high court decision in Australia in the Myriad Genetics Inc. v D'Arcy case...

South AfricaIntellectual Property

The patentability of genetic material has again come into the spotlight with the recent high court decision in Australia in the Myriad Genetics Inc. v D'Arcy case, where the High Court of Australia unanimously ruled that Myriad's patent claims to an isolated nucleic acid coding for a mutant or polymorphic BRCA1 polypeptide was not patentable subject matter. The detection of mutations in the BRCA1 gene is able to be used as a diagnostic marker for the risk of a woman developing breast cancer.  The high court decision was similar to the present position in the United States (US), where a number of US Supreme Court decisions have found that isolated genetic material is not patentable. 

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from